Advances in Pluripotent Stem Cell-Based Cell Therapies

LI Jinze^1,2,3, CHENG Tao^1,2, SHEN Jun^1,2*

(¹State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; ²Tianjin Institutes of Health Science, Tianjin 301600, China;³School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China)

Abstract:

Since the successful establishment of embryonic stem cell and induced pluripotent stem cell lines, pluripotent stem cells have become an important platform in regenerative medicine due to their potential in self-renewal and multilineage differentiation. These cells have not only significantly advanced the understanding of the mechanisms governing cell fate regulation but also provided new strategies and hope for the treatment of various refractory diseases. With the continuous maturation of directed differentiation technologies, functional cells derived from pluripotent stem cells, including blood cells, cardiomyocytes, neurons and pancreatic islet cells, have progressively entered the clinical research stage as “living drugs,” forming diverse drug development pipelines. This review systematically summarizes human pluripotent stem cell-derived cell products that have advanced to clinical trials, analyzes their industrialization pathways and clinical progress, highlights representative achievements, and offers perspectives on future developments in the field, aiming to provide valuable insights for both scientific exploration and clinical translation.

CSTR: 32200.14.cjcb.2026.01.0007